The global Varicella Live Vaccine market was valued at US$ 4174 million in 2023 and is anticipated to reach US$ 5581.5 million by 2030, witnessing a CAGR of 4.3% during the forecast period 2024-2030.

Varicella Live Vaccine Market

The varicella vaccine protects against chickenpox (varicella), a common and very contagious childhood viral illness. It also protects against shingles. It is a live attenuated vaccine, which means it contains a weakened form of the virus.

The global pharmaceutical market is 1475 billion USD in 2022, growing at a CAGR of 5% during the next six years. The pharmaceutical market includes chemical drugs and biological drugs. For biologics is expected to 381 billion USD in 2022. In comparison, the chemical drug market is estimated to increase from 1005 billion in 2018 to 1094 billion U.S. dollars in 2022. The pharmaceutical market factors such as increasing demand for healthcare, technological advancements, and the rising prevalence of chronic diseases, increase in funding from private & government organizations for development of pharmaceutical manufacturing segments and rise in R&D activities for drugs. However, the industry also faces challenges such as stringent regulations, high costs of research and development, and patent expirations. Companies need to continuously innovate and adapt to these challenges to stay competitive in the market and ensure their products reach patients in need. Additionally, the COVID-19 pandemic has highlighted the importance of vaccine development and supply chain management, further emphasizing the need for pharmaceutical companies to be agile and responsive to emerging public health needs.

This report aims to provide a comprehensive presentation of the global market for Varicella Live Vaccine, with both quantitative and qualitative analysis, to help readers develop business/growth strategies, assess the market competitive situation, analyze their position in the current marketplace, and make informed business decisions regarding Varicella Live Vaccine.

Report Scope

The Varicella Live Vaccine market size, estimations, and forecasts are provided in terms of sales volume (K Doses) and revenue ($ millions), considering 2023 as the base year, with history and forecast data for the period from 2019 to 2030. This report segments the global Varicella Live Vaccine market comprehensively. Regional market sizes, concerning products by Type, by Application, and by players, are also provided.

For a more in-depth understanding of the market, the report provides profiles of the competitive landscape, key competitors, and their respective market ranks. The report also discusses technological trends and new product developments.

The report will help the Varicella Live Vaccine manufacturers, new entrants, and industry chain related companies in this market with information on the revenues, sales volume, and average price for the overall market and the sub-segments across the different segments, by company, by Type, by Application, and by regions.

Market Segmentation

Scope of Varicella Live Vaccine Market Report

Report Metric	Details
Report Name	Varicella Live Vaccine Market
Accounted market size in 2023	US$ 4174 million
Forecasted market size in 2030	US$ 5581.5 million
CAGR	4.3%
Base Year	2023
Forecasted years	2024 - 2030
Segment by Type	Monovalent Vaccines Multivalent Vaccines
Segment by Application	Chicken Pox Immunization Herpes Zoster Immunization Measles Immunization Others
Consumption by Region	North America (United States, Canada) Europe (Germany, France, UK, Italy, Russia) Asia-Pacific (China, Japan, South Korea, Taiwan) Southeast Asia (India) Latin America (Mexico, Brazil)
By Company	Astellas Pharma Inc., CSL Limited, Emergent BioSolutions, Inc., GlaxoSmithKline plc, Johnson & Johnson, MedImmune, LLC, Merck & Co., Inc., Pfizer, Inc., Sanofi Pasteur, Serum Institute of India Pvt. Ltd., Bavarian Nordic, Mitsubishi Tanabe Pharma Corporation, Daiichi Sankyo, Biological E, Panacea Biotec
Forecast units	USD million in value
Report coverage	Revenue and volume forecast, company share, competitive landscape, growth factors and trends

Chapter Outline

Chapter 1: Introduces the report scope of the report, executive summary of different market segments (by region, by Type, by Application, etc), including the market size of each market segment, future development potential, and so on. It offers a high-level view of the current state of the market and its likely evolution in the short to mid-term, and long term.
Chapter 2: Detailed analysis of Varicella Live Vaccine manufacturers competitive landscape, price, sales and revenue market share, latest development plan, merger, and acquisition information, etc.
Chapter 3: Sales, revenue of Varicella Live Vaccine in regional level and country level. It provides a quantitative analysis of the market size and development potential of each region and its main countries and introduces the market development, future development prospects, market space, and market size of each country in the world.
Chapter 4: Provides the analysis of various market segments by Type, covering the market size and development potential of each market segment, to help readers find the blue ocean market in different market segments.
Chapter 5: Provides the analysis of various market segments by Application, covering the market size and development potential of each market segment, to help readers find the blue ocean market in different downstream markets.
Chapter 6: Provides profiles of key players, introducing the basic situation of the main companies in the market in detail, including product sales, revenue, price, gross margin, product introduction, recent development, etc.
Chapter 7: Analysis of industrial chain, including the upstream and downstream of the industry.
Chapter 8: Introduces the market dynamics, latest developments of the market, the driving factors and restrictive factors of the market, the challenges and risks faced by manufacturers in the industry, and the analysis of relevant policies in the industry.
Chapter 9: The main points and conclusions of the report.

FAQ for this report

How fast is Varicella Live Vaccine Market growing?

Ans: The Varicella Live Vaccine Market witnessing a CAGR of 4.3% during the forecast period 2024-2030.

What is the Varicella Live Vaccine Market size in 2030?

Ans: The Varicella Live Vaccine Market size in 2030 will be US$ 5581.5 million.

Who are the main players in the Varicella Live Vaccine Market report?

Ans: The main players in the Varicella Live Vaccine Market are Astellas Pharma Inc., CSL Limited, Emergent BioSolutions, Inc., GlaxoSmithKline plc, Johnson & Johnson, MedImmune, LLC, Merck & Co., Inc., Pfizer, Inc., Sanofi Pasteur, Serum Institute of India Pvt. Ltd., Bavarian Nordic, Mitsubishi Tanabe Pharma Corporation, Daiichi Sankyo, Biological E, Panacea Biotec

What are the Application segmentation covered in the Varicella Live Vaccine Market report?

Ans: The Applications covered in the Varicella Live Vaccine Market report are Chicken Pox Immunization, Herpes Zoster Immunization, Measles Immunization, Others

What are the Type segmentation covered in the Varicella Live Vaccine Market report?

Ans: The Types covered in the Varicella Live Vaccine Market report are Monovalent Vaccines, Multivalent Vaccines

1 Varicella Live Vaccine Market Overview

1.1 Product Overview and Scope of Varicella Live Vaccine

1.2 Varicella Live Vaccine Segment by Type

1.2.1 Global Varicella Live Vaccine Market Value Comparison by Type (2024-2030)

1.2.2 Monovalent Vaccines

1.2.3 Multivalent Vaccines

1.3 Varicella Live Vaccine Segment by Application

1.3.1 Global Varicella Live Vaccine Market Value by Application: (2024-2030)

1.3.2 Chicken Pox Immunization

1.3.3 Herpes Zoster Immunization

1.3.4 Measles Immunization

1.3.5 Others

1.4 Global Varicella Live Vaccine Market Size Estimates and Forecasts

1.4.1 Global Varicella Live Vaccine Revenue 2019-2030

1.4.2 Global Varicella Live Vaccine Sales 2019-2030

1.4.3 Global Varicella Live Vaccine Market Average Price (2019-2030)

1.5 Assumptions and Limitations

2 Varicella Live Vaccine Market Competition by Manufacturers

2.1 Global Varicella Live Vaccine Sales Market Share by Manufacturers (2019-2024)

2.2 Global Varicella Live Vaccine Revenue Market Share by Manufacturers (2019-2024)

2.3 Global Varicella Live Vaccine Average Price by Manufacturers (2019-2024)

2.4 Global Varicella Live Vaccine Industry Ranking 2022 VS 2023 VS 2024

2.5 Global Key Manufacturers of Varicella Live Vaccine, Manufacturing Sites & Headquarters

2.6 Global Key Manufacturers of Varicella Live Vaccine, Product Type & Application

2.7 Varicella Live Vaccine Market Competitive Situation and Trends

2.7.1 Varicella Live Vaccine Market Concentration Rate

2.7.2 The Global Top 5 and Top 10 Largest Varicella Live Vaccine Players Market Share by Revenue

2.7.3 Global Varicella Live Vaccine Market Share by Company Type (Tier 1, Tier 2 and Tier 3)

2.8 Manufacturers Mergers & Acquisitions, Expansion Plans

3 Varicella Live Vaccine Retrospective Market Scenario by Region

3.1 Global Varicella Live Vaccine Market Size by Region: 2019 Versus 2023 Versus 2030

3.2 Global Varicella Live Vaccine Global Varicella Live Vaccine Sales by Region: 2019-2030

3.2.1 Global Varicella Live Vaccine Sales by Region: 2019-2024

3.2.2 Global Varicella Live Vaccine Sales by Region: 2025-2030

3.3 Global Varicella Live Vaccine Global Varicella Live Vaccine Revenue by Region: 2019-2030

3.3.1 Global Varicella Live Vaccine Revenue by Region: 2019-2024

3.3.2 Global Varicella Live Vaccine Revenue by Region: 2025-2030

3.4 North America Varicella Live Vaccine Market Facts & Figures by Country

3.4.1 North America Varicella Live Vaccine Market Size by Country: 2019 VS 2023 VS 2030

3.4.2 North America Varicella Live Vaccine Sales by Country (2019-2030)

3.4.3 North America Varicella Live Vaccine Revenue by Country (2019-2030)

3.4.4 U.S.

3.4.5 Canada

3.5 Europe Varicella Live Vaccine Market Facts & Figures by Country

3.5.1 Europe Varicella Live Vaccine Market Size by Country: 2019 VS 2023 VS 2030

3.5.2 Europe Varicella Live Vaccine Sales by Country (2019-2030)

3.5.3 Europe Varicella Live Vaccine Revenue by Country (2019-2030)

3.5.4 Germany

3.5.5 France

3.5.6 U.K.

3.5.7 Italy

3.5.8 Russia

3.6 Asia Pacific Varicella Live Vaccine Market Facts & Figures by Country

3.6.1 Asia Pacific Varicella Live Vaccine Market Size by Country: 2019 VS 2023 VS 2030

3.6.2 Asia Pacific Varicella Live Vaccine Sales by Country (2019-2030)

3.6.3 Asia Pacific Varicella Live Vaccine Revenue by Country (2019-2030)

3.6.4 China

3.6.5 Japan

3.6.6 South Korea

3.6.7 India

3.6.8 Australia

3.6.9 Taiwan

3.6.10 Indonesia

3.6.11 Thailand

3.6.12 Malaysia

3.6.13 Philippines

3.7 Latin America Varicella Live Vaccine Market Facts & Figures by Country

3.7.1 Latin America Varicella Live Vaccine Market Size by Country: 2019 VS 2023 VS 2030

3.7.2 Latin America Varicella Live Vaccine Sales by Country (2019-2030)

3.7.3 Latin America Varicella Live Vaccine Revenue by Country (2019-2030)

3.7.4 Mexico

3.7.5 Brazil

3.7.6 Argentina

3.8 Middle East and Africa Varicella Live Vaccine Market Facts & Figures by Country

3.8.1 Middle East and Africa Varicella Live Vaccine Market Size by Country: 2019 VS 2023 VS 2030

3.8.2 Middle East and Africa Varicella Live Vaccine Sales by Country (2019-2030)

3.8.3 Middle East and Africa Varicella Live Vaccine Revenue by Country (2019-2030)

3.8.4 Turkey

3.8.5 Saudi Arabia

3.8.6 U.A.E

4 Segment by Type

4.1 Global Varicella Live Vaccine Sales by Type (2019-2030)

4.1.1 Global Varicella Live Vaccine Sales by Type (2019-2024)

4.1.2 Global Varicella Live Vaccine Sales by Type (2025-2030)

4.1.3 Global Varicella Live Vaccine Sales Market Share by Type (2019-2030)

4.2 Global Varicella Live Vaccine Revenue by Type (2019-2030)

4.2.1 Global Varicella Live Vaccine Revenue by Type (2019-2024)

4.2.2 Global Varicella Live Vaccine Revenue by Type (2025-2030)

4.2.3 Global Varicella Live Vaccine Revenue Market Share by Type (2019-2030)

4.3 Global Varicella Live Vaccine Price by Type (2019-2030)

5 Segment by Application

5.1 Global Varicella Live Vaccine Sales by Application (2019-2030)

5.1.1 Global Varicella Live Vaccine Sales by Application (2019-2024)

5.1.2 Global Varicella Live Vaccine Sales by Application (2025-2030)

5.1.3 Global Varicella Live Vaccine Sales Market Share by Application (2019-2030)

5.2 Global Varicella Live Vaccine Revenue by Application (2019-2030)

5.2.1 Global Varicella Live Vaccine Revenue by Application (2019-2024)

5.2.2 Global Varicella Live Vaccine Revenue by Application (2025-2030)

5.2.3 Global Varicella Live Vaccine Revenue Market Share by Application (2019-2030)

5.3 Global Varicella Live Vaccine Price by Application (2019-2030)

6 Key Companies Profiled

6.1 Astellas Pharma Inc.

6.1.1 Astellas Pharma Inc. Corporation Information

6.1.2 Astellas Pharma Inc. Description and Business Overview

6.1.3 Astellas Pharma Inc. Varicella Live Vaccine Sales, Revenue and Gross Margin (2019-2024)

6.1.4 Astellas Pharma Inc. Varicella Live Vaccine Product Portfolio

6.1.5 Astellas Pharma Inc. Recent Developments/Updates

6.2 CSL Limited

6.2.1 CSL Limited Corporation Information

6.2.2 CSL Limited Description and Business Overview

6.2.3 CSL Limited Varicella Live Vaccine Sales, Revenue and Gross Margin (2019-2024)

6.2.4 CSL Limited Varicella Live Vaccine Product Portfolio

6.2.5 CSL Limited Recent Developments/Updates

6.3 Emergent BioSolutions, Inc.

6.3.1 Emergent BioSolutions, Inc. Corporation Information

6.3.2 Emergent BioSolutions, Inc. Description and Business Overview

6.3.3 Emergent BioSolutions, Inc. Varicella Live Vaccine Sales, Revenue and Gross Margin (2019-2024)

6.3.4 Emergent BioSolutions, Inc. Varicella Live Vaccine Product Portfolio

6.3.5 Emergent BioSolutions, Inc. Recent Developments/Updates

6.4 GlaxoSmithKline plc

6.4.1 GlaxoSmithKline plc Corporation Information

6.4.2 GlaxoSmithKline plc Description and Business Overview

6.4.3 GlaxoSmithKline plc Varicella Live Vaccine Sales, Revenue and Gross Margin (2019-2024)

6.4.4 GlaxoSmithKline plc Varicella Live Vaccine Product Portfolio

6.4.5 GlaxoSmithKline plc Recent Developments/Updates

6.5 Johnson & Johnson

6.5.1 Johnson & Johnson Corporation Information

6.5.2 Johnson & Johnson Description and Business Overview

6.5.3 Johnson & Johnson Varicella Live Vaccine Sales, Revenue and Gross Margin (2019-2024)

6.5.4 Johnson & Johnson Varicella Live Vaccine Product Portfolio

6.5.5 Johnson & Johnson Recent Developments/Updates

6.6 MedImmune, LLC

6.6.1 MedImmune, LLC Corporation Information

6.6.2 MedImmune, LLC Description and Business Overview

6.6.3 MedImmune, LLC Varicella Live Vaccine Sales, Revenue and Gross Margin (2019-2024)

6.6.4 MedImmune, LLC Varicella Live Vaccine Product Portfolio

6.6.5 MedImmune, LLC Recent Developments/Updates

6.7 Merck & Co., Inc.

6.6.1 Merck & Co., Inc. Corporation Information

6.6.2 Merck & Co., Inc. Description and Business Overview

6.6.3 Merck & Co., Inc. Varicella Live Vaccine Sales, Revenue and Gross Margin (2019-2024)

6.4.4 Merck & Co., Inc. Varicella Live Vaccine Product Portfolio

6.7.5 Merck & Co., Inc. Recent Developments/Updates

6.8 Pfizer, Inc.

6.8.1 Pfizer, Inc. Corporation Information

6.8.2 Pfizer, Inc. Description and Business Overview

6.8.3 Pfizer, Inc. Varicella Live Vaccine Sales, Revenue and Gross Margin (2019-2024)

6.8.4 Pfizer, Inc. Varicella Live Vaccine Product Portfolio

6.8.5 Pfizer, Inc. Recent Developments/Updates

6.9 Sanofi Pasteur

6.9.1 Sanofi Pasteur Corporation Information

6.9.2 Sanofi Pasteur Description and Business Overview

6.9.3 Sanofi Pasteur Varicella Live Vaccine Sales, Revenue and Gross Margin (2019-2024)

6.9.4 Sanofi Pasteur Varicella Live Vaccine Product Portfolio

6.9.5 Sanofi Pasteur Recent Developments/Updates

6.10 Serum Institute of India Pvt. Ltd.

6.10.1 Serum Institute of India Pvt. Ltd. Corporation Information

6.10.2 Serum Institute of India Pvt. Ltd. Description and Business Overview

6.10.3 Serum Institute of India Pvt. Ltd. Varicella Live Vaccine Sales, Revenue and Gross Margin (2019-2024)

6.10.4 Serum Institute of India Pvt. Ltd. Varicella Live Vaccine Product Portfolio

6.10.5 Serum Institute of India Pvt. Ltd. Recent Developments/Updates

6.11 Bavarian Nordic

6.11.1 Bavarian Nordic Corporation Information

6.11.2 Bavarian Nordic Varicella Live Vaccine Description and Business Overview

6.11.3 Bavarian Nordic Varicella Live Vaccine Sales, Revenue and Gross Margin (2019-2024)

6.11.4 Bavarian Nordic Varicella Live Vaccine Product Portfolio

6.11.5 Bavarian Nordic Recent Developments/Updates

6.12 Mitsubishi Tanabe Pharma Corporation

6.12.1 Mitsubishi Tanabe Pharma Corporation Corporation Information

6.12.2 Mitsubishi Tanabe Pharma Corporation Varicella Live Vaccine Description and Business Overview

6.12.3 Mitsubishi Tanabe Pharma Corporation Varicella Live Vaccine Sales, Revenue and Gross Margin (2019-2024)

6.12.4 Mitsubishi Tanabe Pharma Corporation Varicella Live Vaccine Product Portfolio

6.12.5 Mitsubishi Tanabe Pharma Corporation Recent Developments/Updates

6.13 Daiichi Sankyo

6.13.1 Daiichi Sankyo Corporation Information

6.13.2 Daiichi Sankyo Varicella Live Vaccine Description and Business Overview

6.13.3 Daiichi Sankyo Varicella Live Vaccine Sales, Revenue and Gross Margin (2019-2024)

6.13.4 Daiichi Sankyo Varicella Live Vaccine Product Portfolio

6.13.5 Daiichi Sankyo Recent Developments/Updates

6.14 Biological E

6.14.1 Biological E Corporation Information

6.14.2 Biological E Varicella Live Vaccine Description and Business Overview

6.14.3 Biological E Varicella Live Vaccine Sales, Revenue and Gross Margin (2019-2024)

6.14.4 Biological E Varicella Live Vaccine Product Portfolio

6.14.5 Biological E Recent Developments/Updates

6.15 Panacea Biotec

6.15.1 Panacea Biotec Corporation Information

6.15.2 Panacea Biotec Varicella Live Vaccine Description and Business Overview

6.15.3 Panacea Biotec Varicella Live Vaccine Sales, Revenue and Gross Margin (2019-2024)

6.15.4 Panacea Biotec Varicella Live Vaccine Product Portfolio

6.15.5 Panacea Biotec Recent Developments/Updates

7 Industry Chain and Sales Channels Analysis

7.1 Varicella Live Vaccine Industry Chain Analysis

7.2 Varicella Live Vaccine Key Raw Materials

7.2.1 Key Raw Materials

7.2.2 Raw Materials Key Suppliers

7.3 Varicella Live Vaccine Production Mode & Process

7.4 Varicella Live Vaccine Sales and Marketing

7.4.1 Varicella Live Vaccine Sales Channels

7.4.2 Varicella Live Vaccine Distributors

7.5 Varicella Live Vaccine Customers

8 Varicella Live Vaccine Market Dynamics

8.1 Varicella Live Vaccine Industry Trends

8.2 Varicella Live Vaccine Market Drivers

8.3 Varicella Live Vaccine Market Challenges

8.4 Varicella Live Vaccine Market Restraints

9 Research Finding and Conclusion

10 Methodology and Data Source

10.1 Methodology/Research Approach

10.1.1 Research Programs/Design

10.1.2 Market Size Estimation

10.1.3 Market Breakdown and Data Triangulation

10.2 Data Source

10.2.1 Secondary Sources

10.2.2 Primary Sources

10.3 Author List

10.4 Disclaimer

FEATURED COMPANIES

Astellas Pharma Inc

CSL Limited

Emergent BioSolutions Inc

Serum Institute of India Pvt. Ltd

Bavarian Nordic

Mitsubishi Tanabe Pharma Corporation

Daiichi Sankyo

Biological E.

Panacea Biotec

List of Tables

Table 1. Global Varicella Live Vaccine Market Value Comparison by Type (2024-2030) & (US$ Million)

Table 2. Global Varicella Live Vaccine Market Value Comparison by Application (2024-2030) & (US$ Million)

Table 3. Global Varicella Live Vaccine Market Competitive Situation by Manufacturers in 2023

Table 4. Global Varicella Live Vaccine Sales (K Doses) of Key Manufacturers (2019-2024)

Table 5. Global Varicella Live Vaccine Sales Market Share by Manufacturers (2019-2024)

Table 6. Global Varicella Live Vaccine Revenue (US$ Million) by Manufacturers (2019-2024)

Table 7. Global Varicella Live Vaccine Revenue Share by Manufacturers (2019-2024)

Table 8. Global Market Varicella Live Vaccine Average Price (USD/Dose) of Key Manufacturers (2019-2024)

Table 9. Global Key Players of Varicella Live Vaccine, Industry Ranking, 2022 VS 2023 VS 2024

Table 10. Global Key Manufacturers of Varicella Live Vaccine, Manufacturing Sites & Headquarters

Table 11. Global Key Manufacturers of Varicella Live Vaccine, Product Type & Application

Table 12. Global Key Manufacturers of Varicella Live Vaccine, Date of Enter into This Industry

Table 13. Global Manufacturers Market Concentration Ratio (CR5 and HHI)

Table 14. Global Varicella Live Vaccine by Company Type (Tier 1, Tier 2, and Tier 3) & (based on the Revenue in Varicella Live Vaccine as of 2023)

Table 15. Manufacturers Mergers & Acquisitions, Expansion Plans

Table 16. Global Varicella Live Vaccine Market Size by Region (US$ Million): 2019 VS 2023 VS 2030

Table 17. Global Varicella Live Vaccine Sales by Region (2019-2024) & (K Doses)

Table 18. Global Varicella Live Vaccine Sales Market Share by Region (2019-2024)

Table 19. Global Varicella Live Vaccine Sales by Region (2025-2030) & (K Doses)

Table 20. Global Varicella Live Vaccine Sales Market Share by Region (2025-2030)

Table 21. Global Varicella Live Vaccine Revenue by Region (2019-2024) & (US$ Million)

Table 22. Global Varicella Live Vaccine Revenue Market Share by Region (2019-2024)

Table 23. Global Varicella Live Vaccine Revenue by Region (2025-2030) & (US$ Million)

Table 24. Global Varicella Live Vaccine Revenue Market Share by Region (2025-2030)

Table 25. North America Varicella Live Vaccine Revenue by Country: 2019 VS 2023 VS 2030 (US$ Million)

Table 26. North America Varicella Live Vaccine Sales by Country (2019-2024) & (K Doses)

Table 27. North America Varicella Live Vaccine Sales by Country (2025-2030) & (K Doses)

Table 28. North America Varicella Live Vaccine Revenue by Country (2019-2024) & (US$ Million)

Table 29. North America Varicella Live Vaccine Revenue by Country (2025-2030) & (US$ Million)

Table 30. Europe Varicella Live Vaccine Revenue by Country: 2019 VS 2023 VS 2030 (US$ Million)

Table 31. Europe Varicella Live Vaccine Sales by Country (2019-2024) & (K Doses)

Table 32. Europe Varicella Live Vaccine Sales by Country (2025-2030) & (K Doses)

Table 33. Europe Varicella Live Vaccine Revenue by Country (2019-2024) & (US$ Million)

Table 34. Europe Varicella Live Vaccine Revenue by Country (2025-2030) & (US$ Million)

Table 35. Asia Pacific Varicella Live Vaccine Revenue by Region: 2019 VS 2023 VS 2030 (US$ Million)

Table 36. Asia Pacific Varicella Live Vaccine Sales by Region (2019-2024) & (K Doses)

Table 37. Asia Pacific Varicella Live Vaccine Sales by Region (2025-2030) & (K Doses)

Table 38. Asia Pacific Varicella Live Vaccine Revenue by Region (2019-2024) & (US$ Million)

Table 39. Asia Pacific Varicella Live Vaccine Revenue by Region (2025-2030) & (US$ Million)

Table 40. Latin America Varicella Live Vaccine Revenue by Country: 2019 VS 2023 VS 2030 (US$ Million)

Table 41. Latin America Varicella Live Vaccine Sales by Country (2019-2024) & (K Doses)

Table 42. Latin America Varicella Live Vaccine Sales by Country (2025-2030) & (K Doses)

Table 43. Latin America Varicella Live Vaccine Revenue by Country (2019-2024) & (US$ Million)

Table 44. Latin America Varicella Live Vaccine Revenue by Country (2025-2030) & (US$ Million)

Table 45. Middle East & Africa Varicella Live Vaccine Revenue by Country: 2019 VS 2023 VS 2030 (US$ Million)

Table 46. Middle East & Africa Varicella Live Vaccine Sales by Country (2019-2024) & (K Doses)

Table 47. Middle East & Africa Varicella Live Vaccine Sales by Country (2025-2030) & (K Doses)

Table 48. Middle East & Africa Varicella Live Vaccine Revenue by Country (2019-2024) & (US$ Million)

Table 49. Middle East & Africa Varicella Live Vaccine Revenue by Country (2025-2030) & (US$ Million)

Table 50. Global Varicella Live Vaccine Sales (K Doses) by Type (2019-2024)

Table 51. Global Varicella Live Vaccine Sales (K Doses) by Type (2025-2030)

Table 52. Global Varicella Live Vaccine Sales Market Share by Type (2019-2024)

Table 53. Global Varicella Live Vaccine Sales Market Share by Type (2025-2030)

Table 54. Global Varicella Live Vaccine Revenue (US$ Million) by Type (2019-2024)

Table 55. Global Varicella Live Vaccine Revenue (US$ Million) by Type (2025-2030)

Table 56. Global Varicella Live Vaccine Revenue Market Share by Type (2019-2024)

Table 57. Global Varicella Live Vaccine Revenue Market Share by Type (2025-2030)

Table 58. Global Varicella Live Vaccine Price (USD/Dose) by Type (2019-2024)

Table 59. Global Varicella Live Vaccine Price (USD/Dose) by Type (2025-2030)

Table 60. Global Varicella Live Vaccine Sales (K Doses) by Application (2019-2024)

Table 61. Global Varicella Live Vaccine Sales (K Doses) by Application (2025-2030)

Table 62. Global Varicella Live Vaccine Sales Market Share by Application (2019-2024)

Table 63. Global Varicella Live Vaccine Sales Market Share by Application (2025-2030)

Table 64. Global Varicella Live Vaccine Revenue (US$ Million) by Application (2019-2024)

Table 65. Global Varicella Live Vaccine Revenue (US$ Million) by Application (2025-2030)

Table 66. Global Varicella Live Vaccine Revenue Market Share by Application (2019-2024)

Table 67. Global Varicella Live Vaccine Revenue Market Share by Application (2025-2030)

Table 68. Global Varicella Live Vaccine Price (USD/Dose) by Application (2019-2024)

Table 69. Global Varicella Live Vaccine Price (USD/Dose) by Application (2025-2030)

Table 70. Astellas Pharma Inc. Corporation Information

Table 71. Astellas Pharma Inc. Description and Business Overview

Table 72. Astellas Pharma Inc. Varicella Live Vaccine Sales (K Doses), Revenue (US$ Million), Price (USD/Dose) and Gross Margin (2019-2024)

Table 73. Astellas Pharma Inc. Varicella Live Vaccine Product

Table 74. Astellas Pharma Inc. Recent Developments/Updates

Table 75. CSL Limited Corporation Information

Table 76. CSL Limited Description and Business Overview

Table 77. CSL Limited Varicella Live Vaccine Sales (K Doses), Revenue (US$ Million), Price (USD/Dose) and Gross Margin (2019-2024)

Table 78. CSL Limited Varicella Live Vaccine Product

Table 79. CSL Limited Recent Developments/Updates

Table 80. Emergent BioSolutions, Inc. Corporation Information

Table 81. Emergent BioSolutions, Inc. Description and Business Overview

Table 82. Emergent BioSolutions, Inc. Varicella Live Vaccine Sales (K Doses), Revenue (US$ Million), Price (USD/Dose) and Gross Margin (2019-2024)

Table 83. Emergent BioSolutions, Inc. Varicella Live Vaccine Product

Table 84. Emergent BioSolutions, Inc. Recent Developments/Updates

Table 85. GlaxoSmithKline plc Corporation Information

Table 86. GlaxoSmithKline plc Description and Business Overview

Table 87. GlaxoSmithKline plc Varicella Live Vaccine Sales (K Doses), Revenue (US$ Million), Price (USD/Dose) and Gross Margin (2019-2024)

Table 88. GlaxoSmithKline plc Varicella Live Vaccine Product

Table 89. GlaxoSmithKline plc Recent Developments/Updates

Table 90. Johnson & Johnson Corporation Information

Table 91. Johnson & Johnson Description and Business Overview

Table 92. Johnson & Johnson Varicella Live Vaccine Sales (K Doses), Revenue (US$ Million), Price (USD/Dose) and Gross Margin (2019-2024)

Table 93. Johnson & Johnson Varicella Live Vaccine Product

Table 94. Johnson & Johnson Recent Developments/Updates

Table 95. MedImmune, LLC Corporation Information

Table 96. MedImmune, LLC Description and Business Overview

Table 97. MedImmune, LLC Varicella Live Vaccine Sales (K Doses), Revenue (US$ Million), Price (USD/Dose) and Gross Margin (2019-2024)

Table 98. MedImmune, LLC Varicella Live Vaccine Product

Table 99. MedImmune, LLC Recent Developments/Updates

Table 100. Merck & Co., Inc. Corporation Information

Table 101. Merck & Co., Inc. Description and Business Overview

Table 102. Merck & Co., Inc. Varicella Live Vaccine Sales (K Doses), Revenue (US$ Million), Price (USD/Dose) and Gross Margin (2019-2024)

Table 103. Merck & Co., Inc. Varicella Live Vaccine Product

Table 104. Merck & Co., Inc. Recent Developments/Updates

Table 105. Pfizer, Inc. Corporation Information

Table 106. Pfizer, Inc. Description and Business Overview

Table 107. Pfizer, Inc. Varicella Live Vaccine Sales (K Doses), Revenue (US$ Million), Price (USD/Dose) and Gross Margin (2019-2024)

Table 108. Pfizer, Inc. Varicella Live Vaccine Product

Table 109. Pfizer, Inc. Recent Developments/Updates

Table 110. Sanofi Pasteur Corporation Information

Table 111. Sanofi Pasteur Description and Business Overview

Table 112. Sanofi Pasteur Varicella Live Vaccine Sales (K Doses), Revenue (US$ Million), Price (USD/Dose) and Gross Margin (2019-2024)

Table 113. Sanofi Pasteur Varicella Live Vaccine Product

Table 114. Sanofi Pasteur Recent Developments/Updates

Table 115. Serum Institute of India Pvt. Ltd. Corporation Information

Table 116. Serum Institute of India Pvt. Ltd. Description and Business Overview

Table 117. Serum Institute of India Pvt. Ltd. Varicella Live Vaccine Sales (K Doses), Revenue (US$ Million), Price (USD/Dose) and Gross Margin (2019-2024)

Table 118. Serum Institute of India Pvt. Ltd. Varicella Live Vaccine Product

Table 119. Serum Institute of India Pvt. Ltd. Recent Developments/Updates

Table 120. Bavarian Nordic Corporation Information

Table 121. Bavarian Nordic Description and Business Overview

Table 122. Bavarian Nordic Varicella Live Vaccine Sales (K Doses), Revenue (US$ Million), Price (USD/Dose) and Gross Margin (2019-2024)

Table 123. Bavarian Nordic Varicella Live Vaccine Product

Table 124. Bavarian Nordic Recent Developments/Updates

Table 125. Mitsubishi Tanabe Pharma Corporation Corporation Information

Table 126. Mitsubishi Tanabe Pharma Corporation Description and Business Overview

Table 127. Mitsubishi Tanabe Pharma Corporation Varicella Live Vaccine Sales (K Doses), Revenue (US$ Million), Price (USD/Dose) and Gross Margin (2019-2024)

Table 128. Mitsubishi Tanabe Pharma Corporation Varicella Live Vaccine Product

Table 129. Mitsubishi Tanabe Pharma Corporation Recent Developments/Updates

Table 130. Daiichi Sankyo Corporation Information

Table 131. Daiichi Sankyo Description and Business Overview

Table 132. Daiichi Sankyo Varicella Live Vaccine Sales (K Doses), Revenue (US$ Million), Price (USD/Dose) and Gross Margin (2019-2024)

Table 133. Daiichi Sankyo Varicella Live Vaccine Product

Table 134. Daiichi Sankyo Recent Developments/Updates

Table 135. Biological E Corporation Information

Table 136. Biological E Description and Business Overview

Table 137. Biological E Varicella Live Vaccine Sales (K Doses), Revenue (US$ Million), Price (USD/Dose) and Gross Margin (2019-2024)

Table 138. Biological E Varicella Live Vaccine Product

Table 139. Biological E Recent Developments/Updates

Table 140. Panacea Biotec Corporation Information

Table 141. Panacea Biotec Description and Business Overview

Table 142. Panacea Biotec Varicella Live Vaccine Sales (K Doses), Revenue (US$ Million), Price (USD/Dose) and Gross Margin (2019-2024)

Table 143. Panacea Biotec Varicella Live Vaccine Product

Table 144. Panacea Biotec Recent Developments/Updates

Table 145. Key Raw Materials Lists

Table 146. Raw Materials Key Suppliers Lists

Table 147. Varicella Live Vaccine Distributors List

Table 148. Varicella Live Vaccine Customers List

Table 149. Varicella Live Vaccine Market Trends

Table 150. Varicella Live Vaccine Market Drivers

Table 151. Varicella Live Vaccine Market Challenges

Table 152. Varicella Live Vaccine Market Restraints

Table 153. Research Programs/Design for This Report

Table 154. Key Data Information from Secondary Sources

Table 155. Key Data Information from Primary Sources

List of Figures

Figure 1. Product Picture of Varicella Live Vaccine

Figure 2. Global Varicella Live Vaccine Market Value Comparison by Type (2024-2030) & (US$ Million)

Figure 3. Global Varicella Live Vaccine Market Share by Type in 2023 & 2030

Figure 4. Monovalent Vaccines Product Picture

Figure 5. Multivalent Vaccines Product Picture

Figure 6. Global Varicella Live Vaccine Market Value Comparison by Application (2024-2030) & (US$ Million)

Figure 7. Global Varicella Live Vaccine Market Share by Application in 2023 & 2030

Figure 8. Chicken Pox Immunization

Figure 9. Herpes Zoster Immunization

Figure 10. Measles Immunization

Figure 11. Others

Figure 12. Global Varicella Live Vaccine Revenue, (US$ Million), 2019 VS 2023 VS 2030

Figure 13. Global Varicella Live Vaccine Market Size (2019-2030) & (US$ Million)

Figure 14. Global Varicella Live Vaccine Sales (2019-2030) & (K Doses)

Figure 15. Global Varicella Live Vaccine Average Price (USD/Dose) & (2019-2030)

Figure 16. Varicella Live Vaccine Report Years Considered

Figure 17. Varicella Live Vaccine Sales Share by Manufacturers in 2023

Figure 18. Global Varicella Live Vaccine Revenue Share by Manufacturers in 2023

Figure 19. The Global 5 and 10 Largest Varicella Live Vaccine Players: Market Share by Revenue in 2023

Figure 20. Varicella Live Vaccine Market Share by Company Type (Tier 1, Tier 2 and Tier 3): 2019 VS 2023

Figure 21. Global Varicella Live Vaccine Market Size by Region (US$ Million): 2019 VS 2023 VS 2030

Figure 22. North America Varicella Live Vaccine Sales Market Share by Country (2019-2030)

Figure 23. North America Varicella Live Vaccine Revenue Market Share by Country (2019-2030)

Figure 24. U.S. Varicella Live Vaccine Revenue Growth Rate (2019-2030) & (US$ Million)

Figure 25. Canada Varicella Live Vaccine Revenue Growth Rate (2019-2030) & (US$ Million)

Figure 26. Europe Varicella Live Vaccine Sales Market Share by Country (2019-2030)

Figure 27. Europe Varicella Live Vaccine Revenue Market Share by Country (2019-2030)

Figure 28. Germany Varicella Live Vaccine Revenue Growth Rate (2019-2030) & (US$ Million)

Figure 29. France Varicella Live Vaccine Revenue Growth Rate (2019-2030) & (US$ Million)

Figure 30. U.K. Varicella Live Vaccine Revenue Growth Rate (2019-2030) & (US$ Million)

Figure 31. Italy Varicella Live Vaccine Revenue Growth Rate (2019-2030) & (US$ Million)

Figure 32. Russia Varicella Live Vaccine Revenue Growth Rate (2019-2030) & (US$ Million)

Figure 33. Asia Pacific Varicella Live Vaccine Sales Market Share by Region (2019-2030)

Figure 34. Asia Pacific Varicella Live Vaccine Revenue Market Share by Region (2019-2030)

Figure 35. China Varicella Live Vaccine Revenue Growth Rate (2019-2030) & (US$ Million)

Figure 36. Japan Varicella Live Vaccine Revenue Growth Rate (2019-2030) & (US$ Million)

Figure 37. South Korea Varicella Live Vaccine Revenue Growth Rate (2019-2030) & (US$ Million)

Figure 38. India Varicella Live Vaccine Revenue Growth Rate (2019-2030) & (US$ Million)

Figure 39. Australia Varicella Live Vaccine Revenue Growth Rate (2019-2030) & (US$ Million)

Figure 40. Taiwan Varicella Live Vaccine Revenue Growth Rate (2019-2030) & (US$ Million)

Figure 41. Indonesia Varicella Live Vaccine Revenue Growth Rate (2019-2030) & (US$ Million)

Figure 42. Thailand Varicella Live Vaccine Revenue Growth Rate (2019-2030) & (US$ Million)

Figure 43. Malaysia Varicella Live Vaccine Revenue Growth Rate (2019-2030) & (US$ Million)

Figure 44. Philippines Varicella Live Vaccine Revenue Growth Rate (2019-2030) & (US$ Million)

Figure 45. Latin America Varicella Live Vaccine Sales Market Share by Country (2019-2030)

Figure 46. Latin America Varicella Live Vaccine Revenue Market Share by Country (2019-2030)

Figure 47. Mexico Varicella Live Vaccine Revenue Growth Rate (2019-2030) & (US$ Million)

Figure 48. Brazil Varicella Live Vaccine Revenue Growth Rate (2019-2030) & (US$ Million)

Figure 49. Argentina Varicella Live Vaccine Revenue Growth Rate (2019-2030) & (US$ Million)

Figure 50. Middle East & Africa Varicella Live Vaccine Sales Market Share by Country (2019-2030)

Figure 51. Middle East & Africa Varicella Live Vaccine Revenue Market Share by Country (2019-2030)

Figure 52. Turkey Varicella Live Vaccine Revenue Growth Rate (2019-2030) & (US$ Million)

Figure 53. Saudi Arabia Varicella Live Vaccine Revenue Growth Rate (2019-2030) & (US$ Million)

Figure 54. U.A.E Varicella Live Vaccine Revenue Growth Rate (2019-2030) & (US$ Million)

Figure 55. Global Sales Market Share of Varicella Live Vaccine by Type (2019-2030)

Figure 56. Global Revenue Market Share of Varicella Live Vaccine by Type (2019-2030)

Figure 57. Global Varicella Live Vaccine Price (USD/Dose) by Type (2019-2030)

Figure 58. Global Sales Market Share of Varicella Live Vaccine by Application (2019-2030)

Figure 59. Global Revenue Market Share of Varicella Live Vaccine by Application (2019-2030)

Figure 60. Global Varicella Live Vaccine Price (USD/Dose) by Application (2019-2030)

Figure 61. Varicella Live Vaccine Value Chain

Figure 62. Varicella Live Vaccine Production Process

Figure 63. Channels of Distribution (Direct Vs Distribution)

Figure 64. Distributors Profiles

Figure 65. Bottom-up and Top-down Approaches for This Report

Figure 66. Data Triangulation

Figure 67. Key Executives Interviewed

SELECT A FORMAT

Added to Cart

Single User

Electronic (PDF)

$2900

This license allows only one user to access the PDF.

Multi User

Electronic (PDF)

$4350

This license allows 1 - 5 user to access the PDF, license is suitable for small groups of 5 users working together

Enterprise User

Electronic (PDF)

$5800

This license allows users/teams in a same Enterprise to use this report, various departments within an enterpise can use this report

Add to Cart

Buy Now (15% Discount)

HAVE A QUERY?

INQUIRE ABOUT REPORT EMAIL US

OUR CUSTOMER

SIMILAR REPORTS

aluates Reports

Support Contacts

U.S. (TOLL FREE)

+1 (425) 388-2538

sales@valuates.com

THE COMPANY

OUR PRODUCTS

CUSTOMER SUPPORT

CONTACT
FAQ

POLICES

THE COMPANY

ABOUT US

CUSTOMER SUPPORT

CONTACT
FAQ

OUR PRODUCTS

POLICES

Sitemap - Privacy Policy - Terms & Conditions